Lead Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Age ≥ 18 years or older at time of enrollment
•Signed informed consent
•Hematologic disorder requiring allogeneic hematopoietic cell transplantation
•Left ventricular ejection fraction (LVEF) ≥ 45% by multiple uptake gated acquisition (MUGA) scan or echocardiogram
•Forced expiratory volume in one second (FEV1), forced vital capacity (FVC), and diffusing lung capacity oxygenation (DLCO) adjusted ≥ 50% of predicted values on pulmonary function tests
•Transaminases (AST, ALT) \< 3 times upper limit of normal (ULN) values
•Creatinine clearance calculated ≥ 50 mL/min
•Karnofsky Performance Status Score ≥ 60%.
•Human leukocyte antigen (HLA) matched 8/8 (A, B, C, DRB1) related or unrelated donor

•Active infection not controlled with appropriate antimicrobial therapy
•HIV, hepatitis B (HBcAb positive but HBsAg negative with undetectable viral load are eligible), or hepatitis C infection
•Sorror's co-morbidity factors with total score \> 4. Important modification to co-morbidity index calculation: DLCO adjusted will not be included in assessment of pulmonary risk, except those patients with DLCO adjusted \< 50% who are excluded from the trial.
•Anti-thymocyte globulin (ATG) as part of the conditioning regimen
•Cyclophosphamide as part of the conditioning regimen or for GVHD prophylaxis
•Pregnancy
•Histone deacetylase (HDAC), DAC, HSP90 inhibitors or valproic acid for the treatment of cancer within 30 days
•Patients who will need valproic acid for any medical condition during the study or within 5 days prior to first PANO treatment